MX9704030A - 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. - Google Patents

1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.

Info

Publication number
MX9704030A
MX9704030A MX9704030A MX9704030A MX9704030A MX 9704030 A MX9704030 A MX 9704030A MX 9704030 A MX9704030 A MX 9704030A MX 9704030 A MX9704030 A MX 9704030A MX 9704030 A MX9704030 A MX 9704030A
Authority
MX
Mexico
Prior art keywords
thiadiazolidin
heterocyclyloxy
thiomethyl
dioxides
compositions
Prior art date
Application number
MX9704030A
Other languages
English (en)
Other versions
MXPA97004030A (es
Inventor
John J Court
Ranjit C Desai
Dennis John Hlasta
Original Assignee
Sanofi Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Winthrop Inc filed Critical Sanofi Winthrop Inc
Publication of MXPA97004030A publication Critical patent/MXPA97004030A/es
Publication of MX9704030A publication Critical patent/MX9704030A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Cosmetics (AREA)

Abstract

1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona, composiciones farmacéuticas que los contiene y métodos para el tratamiento de enfermedades degenerativas que los emplean.
MX9704030A 1994-12-02 1995-11-30 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. MX9704030A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/348,421 US5494925A (en) 1994-12-02 1994-12-02 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US08348421 1994-12-02
PCT/US1995/015563 WO1996016649A1 (en) 1994-12-02 1995-11-30 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof

Publications (2)

Publication Number Publication Date
MXPA97004030A MXPA97004030A (es) 1998-02-01
MX9704030A true MX9704030A (es) 1998-02-28

Family

ID=23367973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704030A MX9704030A (es) 1994-12-02 1995-11-30 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.

Country Status (12)

Country Link
US (1) US5494925A (es)
EP (1) EP0793494A4 (es)
JP (1) JPH10510535A (es)
CN (1) CN1173130A (es)
AU (1) AU703719B2 (es)
CA (1) CA2205970A1 (es)
FI (1) FI972309A7 (es)
HU (1) HUT77086A (es)
MX (1) MX9704030A (es)
NO (1) NO972451L (es)
NZ (1) NZ297342A (es)
WO (1) WO1996016649A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6420401B1 (en) * 1997-08-22 2002-07-16 Wichita State University 1,2,5, thiadiazolidin-3-one 1,1-dioxide derivatives
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
CN1720240B (zh) * 2002-10-09 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的噻二唑二氧化物和噻二唑氧化物
AU2003300447B2 (en) * 2002-12-30 2009-09-03 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US20080045706A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
JP4939229B2 (ja) * 2003-12-19 2012-05-23 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール
WO2005068460A1 (en) * 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
US20070191336A1 (en) * 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
JP5197016B2 (ja) 2004-12-23 2013-05-15 デシファラ ファーマスーティカルズ， エルエルシー 酵素モジュレータ及び治療
CN101253165A (zh) * 2005-06-29 2008-08-27 先灵公司 作为cxc－化学活素受体配体的二取代的二唑
CA2613428A1 (en) * 2005-06-29 2007-01-11 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
AU2008242720A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
EP2365752B1 (en) * 2008-10-29 2014-09-24 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6228013B2 (ja) * 2013-02-13 2017-11-08 Ｊｘｔｇエネルギー株式会社 潤滑油基油の製造方法
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EA202091763A1 (ru) 2018-01-31 2020-12-14 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Комбинированная терапия для лечения мастоцитоза
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
JP7818502B2 (ja) 2019-08-12 2026-02-20 デシフェラ・ファーマシューティカルズ，エルエルシー 胃腸間質腫瘍を治療するためのリプレチニブ
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
SI4084778T1 (sl) 2019-12-30 2024-01-31 Deciphera Pharmaceuticals, Llc Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2110414T3 (es) * 1989-05-04 1998-02-16 Sanofi Sa Derivados de sacarina utiles como inhibidores de enzimas proteoliticas y su preparacion.
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4141218A1 (de) * 1991-12-13 1993-06-17 Luitpold Werk Chem Pharm Thiadiazincarbonsaeureamidderivate, verfahren zu ihrer herstellung und arzneimittel
US5378720A (en) * 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors

Also Published As

Publication number Publication date
NO972451L (no) 1997-07-25
AU4248396A (en) 1996-06-19
FI972309L (fi) 1997-07-30
US5494925A (en) 1996-02-27
CN1173130A (zh) 1998-02-11
NZ297342A (en) 1999-05-28
WO1996016649A1 (en) 1996-06-06
AU703719B2 (en) 1999-04-01
EP0793494A4 (en) 1998-01-28
EP0793494A1 (en) 1997-09-10
FI972309A7 (fi) 1997-07-30
JPH10510535A (ja) 1998-10-13
HUT77086A (hu) 1998-03-02
NO972451D0 (no) 1997-05-29
CA2205970A1 (en) 1996-06-06
FI972309A0 (fi) 1997-05-30

Similar Documents

Publication Publication Date Title
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
PL340836A1 (en) Novel compounds
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
DE69905170D1 (en) Thiazolopyrimidinderivate
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
IL94278A0 (en) 2-saccharine derivatives,their preparation and pharmaceutical compositions containing them
AU563650B2 (en) Pharmaceutical compositions of benzothiophene derivatives
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
BG105275A (en) Tan-1057 derivatives
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
HU9501925D0 (en) Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
EP0744176A3 (en) Methods for inhibiting bone loss
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
ZA961897B (en) 6,7-substituted-2-aminotetralines and use thereof
MX9802809A (es) Ureasa para el tratamiento de infecciones de helicobacter pylori.
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
GB9615710D0 (en) Pharmaceutical preparations for the treatment of sarcocystosis
IT1269740B (it) Derivati di combretastatine ad attivita' anti-tumorale e procedimento per la loro preparazione
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
AU5024093A (en) Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor